Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • BIOBUSINESS BRIEFS

The next-generation CAR-T therapy landscape

  1. Malvika Verma

    1. Boston Consulting Group, Mountain View, CA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Kyle Obergfell

    1. Boston Consulting Group, Chicago, IL, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Shana Topp

    1. Boston Consulting Group, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Val Panier

    1. Boston Consulting Group, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. John Wu

    1. Boston Consulting Group, Boston, MA, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Chimeric antigen receptor (CAR)-T cell therapies are becoming established as an important treatment modality for cancer. Following the pioneering approval of the CD19-targeted CAR-T therapy tisagenlecleucel by the FDA in 2017, five additional CAR-T therapies have been approved (Supplementary Fig. 1).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 776-777 (2023)

doi: https://doi.org/10.1038/d41573-023-00140-7

Acknowledgements

The authors thank L. Almada-Sabate and J. Yim for contributions to assembling and analysing the database of CAR-T assets. They thank C. Wang for helpful suggestions on recent cell therapy data readouts. The authors thank S. Shah and D. Grossman for their contributions to understanding complexities for the cell therapy field.

Supplementary Information

  1. Supplementary information

Competing Interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by BCG's health care practice.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links